查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1413066

多发性骨髓瘤药物市场：按类型、配销通路- 全球预测 2024-2030 年

Multiple Myeloma Therapeutics Market by Type (Chemotherapy, Radiation, Stem Cell Transplant & Supportive Treatment), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年多发性骨髓瘤治疗市场规模为215.4亿美元，2024年达229.5亿美元，预计2030年将达347.4亿美元，复合年增长率为7.06%。

多发性骨髓瘤药物的全球市场

主要市场统计
基准年[2023] 215.4亿美元
预测年份 [2024] 229.5亿美元
预测年份 [2030] 347.4亿美元
复合年增长率（%） 7.06%
多发性骨髓瘤治疗药物市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估多发性骨髓瘤药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对多发性骨髓瘤治疗市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-多发性骨髓瘤治疗药物市场的市场规模和预测是多少？

2-多发性骨髓瘤药物市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3-多发性骨髓瘤药物市场的技术趋势和法律规范是什么？

4-多发性骨髓瘤治疗市场主要供应商的市场占有率是多少？

5-进入多发性骨髓瘤药物市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 血癌增加
      • 世界各地的老年人口正在增加
      • 对多发性骨髓瘤先进治疗方法的需求不断增长
    • 抑制因素
      • 多发性骨髓瘤治疗费用高昂
    • 机会
      • 多种干细胞移植手术的技术进步
      • 多发性骨髓瘤治疗的持续研究和开发活动
    • 任务
      • 严格的政府规章制度
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章 多发性骨髓瘤药物市场：依类型

  • 化疗
    • 组乙酰酶(HDAC) 抑制剂
    • 免疫调节剂
    • 单株抗体
    • 蛋白酶体抑制剂
    • 常规化疗
  • 辐射
  • 干细胞移植和支持性治疗

第七章 多发性骨髓瘤药物市场：按配销通路

  • 医院药房
  • 网路药房
  • 零售药局和药局

第八章美洲多发性骨髓瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区多发性骨髓瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东及非洲多发性骨髓瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第12章竞争产品组合

  • 主要公司简介
    • AbbVie Inc.
    • Amgen, Inc.
    • Bristol-Myers Squibb Company
    • Celldex Therapeutics, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genzyme Corporation
    • GlaxoSmithKline PLC
    • Innate Pharma SA
    • Johnson & Johnson Services, Inc.
    • Kesios Therapeutics Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
  • 主要产品系列

第十三章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-ED54C46E8368

[195 Pages Report] The Multiple Myeloma Therapeutics Market size was estimated at USD 21.54 billion in 2023 and expected to reach USD 22.95 billion in 2024, at a CAGR 7.06% to reach USD 34.74 billion by 2030.

Global Multiple Myeloma Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 21.54 billion
Estimated Year [2024] USD 22.95 billion
Forecast Year [2030] USD 34.74 billion
CAGR (%) 7.06%
Multiple Myeloma Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multiple Myeloma Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multiple Myeloma Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multiple Myeloma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen, Inc., Bristol-Myers Squibb Company, Celldex Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, GlaxoSmithKline PLC, Innate Pharma SA, Johnson & Johnson Services, Inc., Kesios Therapeutics Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Multiple Myeloma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Chemotherapy
      • Histone Deacetylase (HDAC) Inhibitors
      • Immunomodulating Agents
      • Monoclonal Antibodies
      • Proteasome Inhibitors
      • Traditional Chemotherapy
    • Radiation
    • Stem Cell Transplant & Supportive Treatment
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies & Drug Stores
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multiple Myeloma Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multiple Myeloma Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Multiple Myeloma Therapeutics Market?

4. What is the market share of the leading vendors in the Multiple Myeloma Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Multiple Myeloma Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Multiple Myeloma Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the cases of blood cancers
      • 5.1.1.2. Increasing geriatric population across the globe
      • 5.1.1.3. Growing need for advanced therapeutics for multiple myeloma
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of multiple myeloma
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the multiple stem cell transplant procedures
      • 5.1.3.2. Ongoing research and development activities in multiple myeloma therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict rules and regulations of the government
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Multiple Myeloma Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
    • 6.3.1. Histone Deacetylase (HDAC) Inhibitors
    • 6.3.2. Immunomodulating Agents
    • 6.3.3. Monoclonal Antibodies
    • 6.3.4. Proteasome Inhibitors
    • 6.3.5. Traditional Chemotherapy
  • 6.3. Radiation
  • 6.4. Stem Cell Transplant & Supportive Treatment

7. Multiple Myeloma Therapeutics Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies & Drug Stores

8. Americas Multiple Myeloma Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Multiple Myeloma Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Myeloma Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbbVie Inc.
    • 12.1.2. Amgen, Inc.
    • 12.1.3. Bristol-Myers Squibb Company
    • 12.1.4. Celldex Therapeutics, Inc.
    • 12.1.5. F. Hoffmann-La Roche Ltd.
    • 12.1.6. Genzyme Corporation
    • 12.1.7. GlaxoSmithKline PLC
    • 12.1.8. Innate Pharma SA
    • 12.1.9. Johnson & Johnson Services, Inc.
    • 12.1.10. Kesios Therapeutics Ltd.
    • 12.1.11. Merck & Co., Inc.
    • 12.1.12. Novartis AG
    • 12.1.13. Sanofi S.A.
    • 12.1.14. Takeda Pharmaceutical Company Limited
    • 12.1.15. Teva Pharmaceutical Industries Ltd.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MULTIPLE MYELOMA THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE (HDAC) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TRADITIONAL CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RADIATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANT & SUPPORTIVE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 147. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. MULTIPLE MYELOMA THERAPEUTICS MARKET LICENSE & PRICING